long-term prognostic value of functional status assessment in stable patients with chronic HF.
Methods Study Population
The Cleveland Clinic Genebank study prospectively enrolled a total of 8,987 subjects who underwent coronary angiography in the absence of an acute coronary syndrome, without a history of revascularization within 30 days before enrollment, and $5 years of long term adjudicated follow up data. Detailed med ical histories were obtained on all subjects (predominantly outpa tients) at enrollment. Blood samples were collected at the time of cardiac catheterization after arterial sheath placement, but before the catheterization procedure or any therapy (including anticoagu lation medications). Every participant gave written informed con sent approved by the Institutional Review Board.
Data Collected
The present analysis included 1,700 of consecutive subjects with a medical history of HF with reduced or preserved left ven tricular ejection fraction (LVEF) enrolled in Genebank, who completed the DASI questionnaire (Table 1) and with correspond ing blood samples for analysis. Chronic HF was defined as a docu mented history of HF by treating physician in the electronic medical record and confirmed by study personnel at the time of enrollment. Heart failure was defined as a documented history of HF by the treating cardiologist in the electronic medical record at the time of enrollment.
Biomarkers and Echocardiography
B Type natriuretic peptide (BNP), creatinine, fasting lipid profiles, cardiac troponin I (TnI), uric acid, and high sensitivity C reactive protein (hs CRP) were measured on the Abbot Architect platform (Abbott Laboratories, Abbot Park, Illinois). An estimate of glomerular filtration rate (eGFR) was calculated with the use of the Modification of Diet in Renal Disease equation. LVEF was deter mined via transthoracic echocardiography by the Cleveland Clinic echocardiography laboratory reviewed by Board certified cardio logists with the use of chart review of the electronic medical record.
Adjudicated outcomes were prospectively ascertained over the ensuing 5 years for all subjects after enrollment.
DASI Questionnaire
Patients were asked to complete the DASI survey, supervised by study personnel, at the time of coronary angiography. The DASI is a self administered questionnaire that measures both functional capacity and quality of life aspects. It correlates well with peak oxygen uptake on stress testing. 5 The survey attempts to capture major aspects of physical function: personal hygiene, ambulation, routine tasks, recreation, and sexual function. High scores corre late with better functional capacity. This questionnaire has been validated in similar populations. 7, 8 Statistical Analysis
This cohort was split into quartiles of DASI score for the pop ulation. P values of #.05 were considered to be significant to reject the null hypothesis that there were no differences in mortal ity at 5 years of follow up between the highest and lowest DASI score quartiles. Independent variable was DASI score quartile, and dependent variable was mortality at 5 years. Parametric and nonparametric approaches were used to express continuous vari ables. Survival analyses were completed with the use of the Kaplan Meier method and log rank analysis to compare survival curves among the 4 quartiles. Cox proportional hazards models were used to compare time to event analyses to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for 5 year morta lity between the 1st and 4th quartiles of DASI scores. Multivariate models were adjusted for traditional cardiac risk factors, including age, sex, systolic blood pressure, cigarette smoking, history of dia betes, and fasting low density lipoprotein and high density lipo protein cholesterol levels. Additional adjustments were made for a subset with both measured BNP and eGFR values. Subgroups were divided according to age $60 years, LVEF !45%, eGFR !60 mL min À1 1.73 m À2 , history of coronary artery disease (CAD), TnI $0.03 ng/mL, sex, uric acid $9.8 mg/dL, hs CRP $2 mg/dL, history of diabetes mellitus, and history of chronic obstructive pulmonary disease (COPD). Statistical ana lyses were performed with the use of JMP Pro version 9 (SAS Institute, Cary, North Carolina).
Results
Baseline characteristics are described in Table 2 and are representative of a patient population with chronic HF. The reasons for cardiac catheterization within the study cohort were as follows (subjects can have O1 reason): history of positive or abnormal stress test (30%), evaluation for possible ischemic causes of symptoms (63.5%), preoperative evaluation (24%), and history of cardiomyopathy (14%). DASI surveys were successfully completed by 1,700 study participants, and scores across this study cohort were nonparametrically distributed (Fig. 1) . The median DASI score was 26.2 (interquartile range 15.5 42.7). The mean DASI scores for quartiles 1 4 were 8.7 6 3.7, 20.2 6 3.2, 33.4 6 3.9, and 50.0 6 5.9, respectively. Decreasing DASI scores were associated with increasing comorbidity (Table 2 ), but not with LVEF (P 5 .4). There were no differences in either angiotensin-converting In our study cohort, 1,692 study participants were followed for all-cause mortality over 5 years after study entry. By 5 years there were a total of 556 deaths and 1,023 subjects survived to the end of follow-up. 113 study participants were lost to follow-up. Kaplan-Meier estimates of survival were calculated for 1,692 participants (Fig. 2) . The estimated 5-year survival rate was 67%. DASI score quartiles 1 4 had 193, 166, 120, and 77 deaths, respectively, by the end of follow-up. There were significant decrements in survival across increasing DASI score quartiles: log-rank chi-square 96.1; P ! .0001. The lowest DASI score quartile predicted a 3.3-fold increase in risk of 5-year mortality compared with the highest DASI score quartile: HR 3.33, 95% CI 2.57 4.36; P ! .0001; Table 3 ). After additional adjustment for traditional risk factors, lower DASI scores still independently predicted an increased risk for death: HR 2.78, 95% CI 2.10 3.72; P ! .0001. Furthermore, when stratifying DASI score by median (26.2) , in addition to multivariate adjustment for traditional risk factors, the area under the receiver operating characteristic curve for 5-year mortality was 69.4%. In a sensitivity analysis with multivariate adjustment for LVEF in addition to traditional risk factors, lower DASI scores remained predictive of increased mortality: HR 2.79, 95% CI 2.10 3.72; P ! .0001. Compared with DASI scores O40, DASI scores #40 predicted a 2-fold increased risk for death: HR 2.00, 95% CI 1.58 2.58; P ! .0001. Subgroup analyses reveal that DASI scores predict all-cause mortality across dichotomized subgroups of age, sex, history of coronary artery disease, history of diabetes mellitus, history of COPD, eGFR, and LVEF (Fig. 3) 
Prognostic Value of DASI Adjusting for Cardiorenal Biomarkers
In a subset of patients with available BNP data (Fig. 4) at the time of the DASI questionnaire, we observed only a modest correlation between BNP (Spearman rho 5 0.210; P ! .0001) and DASI score. Estimated glomerular filtration rate was also modestly correlated with DASI score (Spearman rho 5 0.107; P ! .0001) for the total cohort. Lower DASI scores still independently predicted an increased risk for death after adjusting for traditional risk factors, BNP, and eGFR: HR 2.57, 95% CI 1.64 4.15; P ! .0001).
Discussion
There are several key findings in our study. First, we surveyed a large cohort of patients with chronic stable HF undergoing elective coronary evaluation and observed an association between lower functional status (as measured with the use of the DASI questionnaire) and greater risk of 5-year mortality. Second, this association remained robust after multivariate adjustment for traditional cardiac risk factors and, in a subset of patients, after additional adjustment for cardiorenal biomarkers. Although commonly attributed to the underlying comorbid conditions, the association between diminished functional capacity and 5-year all-cause mortality appeared to be consistent across a variety of subgroups of patients with different comorbid conditions and clinical characteristics. Taken together, these findings illustrate the potential of patient-centric insight gained by conducting a simple questionnaire developed to assess overall functional capacity.
Functional capacity is an important component of a patient-centric evaluation of HF, and recommendations for its careful assessment have been included in the latest clinical management guidelines. 9, 10 Although the DASI Subset of 800 subjects with biomarker data available. Fig. 3 . Subgroup analysis of Duke Activity Status Index (DASI) score and 5 year mortality. HR, hazard ratio; CI, confidence interval; EF, ejection fraction; eGFR, estimated glomerular filtration rate; CAD, coronary artery disease; TnI, troponin I; hs CRP, high sensitivity C reactive protein; COPD, chronic obstructive pulmonary disease.
was developed O20 years ago, 5 its application has been largely restricted as a subjective assessment tool in clinical trials. The DASI is a simple self-administered questionnaire that assesses perceived functional status. Rather than relying on recall, it is composed of questions relating to self-assessment of one's ability to perform activities that represent major aspects of physical function. Set up as a continuous measure, DASI scores correlate with peak oxygen uptake during cardiopulmonary stress testing. 5 The DASI has been validated in cohorts of patients with HF, obstructive CAD, and COPD. 5, 11, 12 Although the accuracy of DASI score in predicting peak oxygen uptake in the setting of HF has been challenged, 8, 13 our findings support the notion that the clinical utility may likely extend beyond performance on stress testing. Indeed, a recent comparison of several commonly used objective assessments of functional capacity did not validate cardiopulmonary exercise stress testing as equivalent to other, simpler, forms of exercise capacity evaluation, such as the 6-minute walk test, in terms of prognostic utility. 14 To our knowledge, this is the largest cohort of patients with HF who have completed the DASI survey and have been followed longitudinally for adverse outcomes. Our findings confirm several smaller studies that have suggested the prognostic value of functional status assessment in the setting of HF. For example, DASI scores were lower in a population of 130 patients with impaired LVEF recently hospitalized for decompensated HF who experienced adverse events after 9 months of follow-up compared with those that did not. 6 Paired with BNP, those with low DASI scores and higher BNP levels were more likely to have lower event-free survival. 6 In adults O75 years old, lower functional status, as measured with the use of the preadmission Barthel Index, was a strong predictor of 3-month mortality. 15 In the setting of cardiac surgery, lower DASI scores have also been associated with higher mortality risk, 16 and changes in DASI scores have been observed after surgery. 17 It has been suggested that DASI scoring may vary based on factors that affect functional capacity, such as age, sex, COPD, and the presence of diabetes mellitus. 18 Yet, based on our findings, its prognostic value in these cohorts remained robust. Additionally, we found that DASI scores correlate with mortality in patients with either reduced or preserved left ventricular function and were not related to systematic differences (eg, ACEI/ARB or betablocker use) in medical management of HF.
There are other prognostic instruments that capture functional status as well. In a cohort of 6,975 outpatients with chronic HF from the Gruppo Italiano per lo Studio Della Streptochinasi Nell'Infarto Miocardico Heart Failure Trial (GISSI-HF), New York Heart Association (NYHA) functional classification III or IV was independently associated with a more adverse prognosis than NYHA functional classification II. 19 NYHA functional class is a simple score ordinally assessing exertional symptoms in HF. Yet it has notable limitations 1 : no consistent assessment method and 1 high interoperator variability. 20 The Minnesota Living With Heart Failure Questionnaire (MLHFQ) is a validated HF-specific questionnaire based on a Likert scale. 21 Data from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) suggests that lower MHLF scores are associated with adverse outcomes in patients with HF with preserved LVEF. 22 In contrast to these scores, the DASI can provide a continuum of scores, and is easily administered with simple yes/no patient responses, either oral or written.
Increasing plasma levels of natriuretic peptides have been associated with adverse outcomes in chronic HF 23 and may provide incremental prognostic information independently from clinical assessment. 24 Furthermore, based on an ancillary study from the Studies on Left Ventricular Dysfunction (SOLVD) trial, worsening renal function is independently associated with both mortality and disease progression in patients with LV dysfunction. 25 Renal function also provides additional prognostic information in patients with HF independently from functional status as measured by the 6-minute walk test. 26 Our observation regarding the incremental prognostic value of DASI after inclusion of BNP and eGFR in multivariate adjustment suggested that factors incremental to cardiorenal disease progression that are captured by the patient's own perception of his or her own functional status may affect long-term outcomes. For example, other underlying metabolic derangements or physical limitations may be uncovered during DASI assessment.
Our results must be interpreted in the context of several limitations in our study design. Because DASI scores were measured at only 1 point in time, we were unable to examine the variability and prognostic value of changing DASI scores over time or the impact of different therapies in the interim. Furthermore, baseline NYHA functional class was unavailable and hospitalization readmissions were not adjudicated. We cannot exclude the presence of unmeasured confounding by baseline depressive symptoms, because these were not assessed on study inclusion, or selection bias for those undergoing coronary angiography for further evaluation and management of HF at a tertiary care center, although based on baseline clinical characteristics they appear to be relatively representative of a contemporary patient population with HF. However, the majority of the patients in this analysis had ischemic cardiomyopathy and there was low use of beta-and reninangiotensin blocking agents. Nevertheless, based on our promising results and in the era where patient-centric outcomes are valued, further investigations into the clinical utility of baseline and serial DASI questionnaire administrations are warranted.
Conclusion
In patients with stable HF, functional status assessment, as measured by the DASI questionnaire, predicts mortality at 5 years. This assessment provides independent and additional prognostic information beyond the measurement of BNP and eGFR. Lower DASI scores predict mortality across a variety of subgroups of differing prognosis in patients with HF. These results highlight the importance of assessing functional status in patients with HF. Future studies using functional status assessment as a tool for treatment intensification in HF are warranted.
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